10x Genomics expanded its single-cell technology portfolio by acquiring Scale Biosciences for an upfront $30 million payment plus performance-based milestones. Scale's split-pool combinatorial barcoding enables instrument-free single-cell experimental scaling, including RNA and methylation profiling. Integration of Scale’s technologies is expected to augment 10x’s Chromium platform capabilities, advancing single-cell analysis scale and multiplexing. Both companies emphasize a shared commitment to continual innovation to address single-cell genomics challenges.